Emerging studies suggest Retatru tide , a dual agonist targeting both incretin and GIP , may offer a promising advancement for weight loss . Early patient tests have indicated substantial decreases in body fat , potentially exceeding existing obesity treatments. Nevertheless , additional evaluation is necessary to completely determine its long-t… Read More